BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.3.6//EN TZID:Europe/Amsterdam X-WR-TIMEZONE:Europe/Amsterdam BEGIN:VEVENT UID:2405@worldglaucomaweek.org DTSTART;TZID=Europe/Amsterdam:20190306T120000 DTEND;TZID=Europe/Amsterdam:20190306T131500 DTSTAMP:20190228T233007Z URL:https://www.worldglaucomaweek.org/activity/luncheon-briefing-to-recogn ize-world-glaucoma-week-2019/ SUMMARY:Congressional Luncheon Briefing to Recognize World Glaucoma Week DESCRIPTION:THE ALLIANCE FOR EYE AND VISION RESEARCH\nIn conjunction with:\ nResearch to Prevent Blindness\nAmerican Glaucoma Society\nAssoc. for Rese arch in Vision and Ophthalmology\nGlaucoma Research Foundation\nOptometric Glaucoma Society\n \;\nLuncheon Briefing to Recognize\nWorld Glaucoma Week 2019 (March 10-16)\nUnderstanding the Genetic Basis of Glaucoma to D evelop Vision Loss  Prevention Strategies\nWednesday\, March 6\, 2019\n12 Noon - 1:15 pm at House Rayburn 2168 (Gold Room)\nFeaturing Speaker\nLoui s R. Pasquale\, MD\, FARVO\nNew York Eye and Ear Infirmary of Mount Sinai\ nIcahn School of Medicine at Mount Sinai\nPlease R.S.V.P. to Dina Beaumont @ 202-407-8325 or dinabeau@aol.com\nAEVR\, a 501(c)3 Non-Profit Education al Foundation\, is pleased to host this widely attended event featuring an eye-healthy luncheon.\n \;\n\nWhat is glaucoma and why is it importan t?\n\nGlaucoma\, the second leading cause of preventable vision loss in th e United States\, is a neurological disease affecting the optic nerve and causing loss of peripheral vision—and ultimately blindness. It affects m ore than 2.7 million Americans over age 40\, with that number estimated to more than double by year 2050. It includes both diagnosed and undiagnosed cases\, as often individuals are unaware that they have the disease until vision is lost. It is a driving factor−along with cataract and diabetic retinopathy−in the annual cost of vision impairment reaching $717 billi on in inflation-adjusted dollars by year 2050.\n\n \;\n\nCertain chara cteristics such as age\, ethnicity\, high blood pressure\, high intraocula r pressure (IOP)\, and optic nerve appearance are associated with disease development. Groups at highest risk include African Americans over age 40\ , individuals over age 60\, and those with a family history of the disease . In its most common form−primary open angle glaucoma (POAG)−nerve dam age results from high IOP\, which occurs when the fluid that circulates in and out of the front part of the eye drains inadequately. Research funded by the National Eye Institute (NEI) within the National Institutes of Hea lth (NIH) has resulted in pressure-reducing drug regimens\, and NEI’s Oc ular Hypertension Treatment Study (OHTS) found that pressure-reducing eye drops delayed disease onset. In addition to drug regimens\, glaucoma is al so treated through traditional and minimally invasive surgical techniques —many including the use of Food and Drug Administration (FDA)-approved d rainage devices to enhance fluid flow to reduce IOP.\n\n \;\n\nWhat is new in the genetic basis of glaucoma and how will it lead to treatments?  \n\nFeatured speaker Louis Pasquale\, MD participates in the NEI Glaucom a Human Genetics Collaboration (NEIGHBOR) Consortium and augmented Glaucom a Gene Environment Initiative (GLAUGEN) Study. These collaborative efforts are under the umbrella of a larger NEIGHBOR Overall Operational Database called the NEIGHBORHOOD that involves clinicians and geneticists at multip le institutions throughout the United States. Through mid-2018\, the conso rtium has identified 133 genetic variants that predict glaucoma risk\, inc luding 68 that had not been linked previously to IOP.  Furthermore\, rese archers found an almost direct correlation between the magnitude of the ge netic variants’ effect on eye pressure and their effect on glaucoma risk —meaning that IOP appears to be the overriding factor that determines wh ether someone develops glaucoma.\n\n \;\n\nAbout the Speaker….\n\nLo uis Pasquale\, MD\, FARVO is a Professor of Ophthalmology at the Icahn Sch ool of Medicine at Mount Sinai Hospital in New York. He is Site Chair of t he Department of Ophthalmology at Mt. Sinai Hospital and Vice Chair of Tra nslational Ophthalmology Research for the Mount Sinai Healthcare System. A fter briefly addressing unmet need and at-risk populations\, he will discu ss the NEIGHBORHOOD findings and how future research can determine whether the genetic variants can identify predictive risk factors that may facili tate better diagnosis of and treatment for the disease. ATTACH;FMTTYPE=image/jpeg:https://www.worldglaucomaweek.org/wp-content/upl oads/2019/02/NYEEI-Sinai-color-JPG.jpg CATEGORIES:Public educational LOCATION:New York Eye and Ear Infirmary of Mount Sinai\, 310 East 14th Stre et\, New York\, New York\, 10003\, United States GEO:40.7318919;-73.98458590000001 X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=310 East 14th Street\, New York\, New York\, 10003\, United States;X-APPLE-RADIUS=100;X-TITLE=New Yor k Eye and Ear Infirmary of Mount Sinai:geo:40.7318919,-73.98458590000001 END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Amsterdam X-LIC-LOCATION:Europe/Amsterdam BEGIN:STANDARD DTSTART:20181028T020000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET END:STANDARD END:VTIMEZONE END:VCALENDAR